融捷健康 reported revenue of ¥0.40B for the period ended 2026-06-30, -8.6% year on year. Net income was ¥0.06B, a 16.3% net margin on a 45.4% gross margin. The largest revenue line is 销售商品 at 99% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.40B | -8.6% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.06B | +0.5% |
| Gross margin | 45.4% | Net margin 16.3% |
| Revenue Q/Q | -35.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 销售商品 | ¥0.39B | 98.9% |
| 其他(补充) | ¥0.00B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.22B | 54.6% |
| R&D | ¥0.01B | 1.7% |
| SG&A | ¥0.09B | 21.8% |
| Tax & other | ¥0.03B | 8.3% |
| Item | Amount |
|---|---|
| Total assets | ¥1.55B |
| Total liabilities | ¥0.25B |
| Shareholders' equity | ¥1.30B |
| Equity / assets | 83.9% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | 27% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新开普 ・ 依米康 ・ 初灵信息 ・ 金信诺 ・ 卫宁健康 ・ 仟源医药 ・ 常山药业 ・ 星星科技 ・ 开山股份 ・ 精锻科技 ・ 新天科技 ・ 新莱应材
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies